Sensei Biotherapeutics, INC 8-K filings

Faeth Therapeutics announced its second quarter 2026 financial results, detailing progress in its PIKTOR clinical trials for endometrial and breast cancer, alongside a substantial increase in cash reserves.

Faeth Therapeutics announced performance-based stock option grants to employees, tied to a $70 stock price hurdle.

Faeth Therapeutics, Inc. has entered into a Sales Agreement to offer and sell up to $150 million of its common stock through TD Securities (USA) LLC.

Sensei Biotherapeutics, Inc. has officially changed its name to Faeth Therapeutics, Inc., effective June 15, 2026, and appointed Anand Parikh as its new President and CEO, alongside other leadership and board changes.

Sensei Biotherapeutics stockholders approved new equity incentive and employee stock purchase plans and authorized a significant increase in common stock.

Sensei Biotherapeutics files pro forma financial data ahead of the June 10, 2026, shareholder vote on Series B Preferred Stock conversion.

Sensei Biotherapeutics announced first quarter 2026 financial results, highlighting the acquisition of Faeth Therapeutics and progress in its PIKTOR clinical trials for breast and endometrial cancer.

Sensei Biotherapeutics has announced a conditional board restructuring and executive leadership transition contingent upon upcoming shareholder approval.

Sensei Biotherapeutics amends prior 8-K filing to include audited financial statements of acquired Faeth Subsidiary and pro forma combined financial information.

Sensei Biotherapeutics narrowed its 2025 net loss, acquired Faeth Therapeutics, and raised $200 million to advance PIKTOR in endometrial and breast cancer.

Sensei Biotherapeutics, Inc. announced the expansion of its board of directors from three to five members, appointing Christopher W. Gerry and Phillip B. Donenberg, effective February 13, 2026.

Sensei Biotherapeutics, Inc. announced new retention agreements for its President and SVP of Finance, increasing their base salaries and introducing retention bonuses.

Sensei Biotherapeutics discontinues its lead product candidate solnerstotug, initiates a strategic review, and reduces its workforce by 65% while reporting Q3 2025 financial results.

Sensei Biotherapeutics announced the discontinuation of solnerstotug development and initiated a comprehensive strategic review to maximize shareholder value, including potential sale or merger.

Sensei Biotherapeutics announced positive Phase 1/2 clinical results for solnerstotug in PD-(L)1 resistant tumors, showing durable progression-free survival and a favorable safety profile.

Sensei Biotherapeutics reported improved second-quarter 2025 financial results and favorable preliminary clinical data for solnerstotug, extending its cash runway into Q2 2026.

Sensei Biotherapeutics, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on The Nasdaq Stock Market LLC.

Sensei Biotherapeutics, Inc. has filed an amendment to its Certificate of Incorporation to effect a one-for-twenty reverse stock split and reduce its authorized common shares from 250 million to 12.5 million, effective June 16, 2025.

Sensei Biotherapeutics held its 2025 annual meeting of stockholders, where key proposals including the election of directors, ratification of the accounting firm, and approval of a reverse stock split were approved.

Sensei Biotherapeutics announces favorable clinical data in PD-(L)1 resistant patients and reports its first quarter 2025 financial results, with a cash runway extending into the second quarter of 2026.

Sensei Biotherapeutics reports encouraging preliminary efficacy data from its Phase 1/2 trial of solnerstotug in PD-(L)1 resistant tumors, along with financial results for 2024 and a cash runway into Q2 2026.

Sensei Biotherapeutics announces favorable initial data from its Phase 1/2 trial of solnerstotug in patients with PD-(L)1 resistant tumors, showing promising clinical activity.

Sensei Biotherapeutics has been granted an extension to regain compliance with Nasdaq's minimum bid price rule after transferring to the Nasdaq Capital Market.

Sensei Biotherapeutics reported its Q3 2024 financial results, highlighted progress in its SNS-101 clinical trial, and announced a strategic restructuring to extend its cash runway.

Deneen Vojta, MD, has resigned from the Sensei Biotherapeutics Board of Directors, effective December 31, 2024, citing personal reasons.

Sensei Biotherapeutics has appointed Josiah Craver as its new principal financial officer and principal accounting officer, effective immediately, replacing interim officer David Gaiero.

Sensei Biotherapeutics announced positive clinical data for its lead candidate SNS-101 and a strong cash position extending into the fourth quarter of 2025.

Sensei Biotherapeutics has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, putting its listing at risk.

Sensei Biotherapeutics announces the resignation of Jessie English, PhD from its Board of Directors, effective July 1, 2024, due to personal reasons.

Sensei Biotherapeutics held its 2024 annual meeting, electing three directors and ratifying Deloitte & Touche LLP as its independent auditor.